You are viewing: China Humanized Mouse and Rat Model Market analysis

The China Humanized Mouse and Rat Model Market was valued at $18.1 Million in 2025 and projected to reach to $29.2 Million by 2030, representing a compound annual growth rate of 10.0%. China's humanized mouse and rat model market is positioned for sustained growth through 2030, with the market expanding from $18.1 million in 2025 to $29.2 million by 2030.

China Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Humanized Mouse and Rat Model Market Trends and Insights

  • This 10.0% compound annual growth rate reflects China's accelerating investment in preclinical research infrastructure and biopharmaceutical development.
  • China's growing emphasis on drug discovery and personalized medicine is driving demand for advanced animal models that better replicate human disease pathways. The market growth in China is underpinned by increased government funding for life sciences research and the expansion of contract research organizations (CROs) across major biotech hubs.
  • China's pharmaceutical companies are increasingly adopting humanized mouse and rat models to reduce development timelines and improve drug efficacy predictions.
  • Between 2025 and 2030, China is expected to strengthen its position as a key player in preclinical research, supported by regulatory reforms and rising collaboration between academic institutions and industry partners. China's market trajectory outpaces the global average, reflecting the country's strategic focus on biotechnology innovation and its role in the global drug development supply chain.
  • The integration of humanized models into China's research ecosystem positions the nation as an attractive destination for international pharmaceutical partnerships and contract research services..

Key Market Statistics

  • CAGR (2025-2030) 10.0% CAGR
  • Market Size, 2025 ~USD 18.1 Million
  • Forecast, 2030 ~USD 29.2 Million
  • Country China

China Humanized Mouse and Rat Model Market Overview

Rapid Market Expansion :

China's humanized mouse and rat model market is growing at 10% CAGR, significantly outpacing the global rate of 8.2%, driven by increased R&D investments and government support for biopharmaceutical innovation.

Government-Backed Research Initiative :

China's commitment to becoming a global pharmaceutical hub has led to substantial funding for preclinical research infrastructure, making humanized animal models essential for drug development pipelines.

Personalized Medicine Adoption :

Growing emphasis on precision medicine and tailored therapeutics in China is accelerating demand for humanized models that better predict human drug responses and reduce clinical trial failures.

Biotech Ecosystem Growth :

Expansion of Chinese biotech companies and CROs in major hubs like Shanghai, Beijing, and Shenzhen is creating sustained demand for advanced preclinical research tools and humanized animal models.

China Humanized Mouse and Rat Model Market Dynamics

  • This trajectory reflects China's strategic pivot toward high-value pharmaceutical research and development, supported by government initiatives promoting domestic drug discovery capabilities.
  • The increasing number of biotech startups and established pharmaceutical companies investing in preclinical research infrastructure will continue to drive adoption of humanized models. Key growth drivers include rising R&D expenditures, regulatory support for innovative therapies, and collaboration between academic institutions and industry.
  • As China strengthens its position in global drug development, humanized animal models will become increasingly critical for reducing development timelines and improving clinical success rates.
  • Market players should anticipate growing competition and opportunities in providing specialized models tailored to Chinese research needs..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • China's humanized mouse and rat model market is valued at $18.1 million in 2025 and is forecast to grow to $29.2 million by 2030, representing a 10.0% CAGR.
    • China's market growth rate exceeds the global average, driven by increased government R&D funding and expansion of domestic CROs.
    • China's pharmaceutical and biotech sectors are rapidly adopting humanized models to accelerate drug development and improve clinical trial success rates.
    • China's strategic positioning in global drug development supply chains and regulatory reforms are expected to sustain market momentum through 2030.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    China Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC AND RESEARCH INSTITUTES2.933.23.53.744.24.57
    CROS & CDMOS5.15.56.16.87.68.49.310.311.1
    PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES11.211.812.914.315.617.118.620.39.4
    TOTAL19.220.322.224.526.929.432.235.19.6

    Target Audience

    • Pharmaceutical Companies : Chinese and multinational pharma firms need market insights to allocate R&D budgets, establish preclinical research partnerships, and accelerate drug development timelines using humanized models.
    • Biotech & CRO Organizations : Emerging Chinese biotech companies and contract research organizations require market data to validate service offerings, identify customer segments, and plan capacity expansion for humanized model services.
    • Research Institutions & Universities : Academic centers in China need market intelligence to secure funding, establish industry collaborations, and position their humanized model capabilities within the growing preclinical research ecosystem.
    • Investors & Venture Capital : VC firms and institutional investors targeting China's biotech sector require market forecasts and growth drivers to evaluate investment opportunities in humanized model providers and research platforms.
    • Model Suppliers & Technology Vendors : Global and regional suppliers of humanized animal models, breeding services, and related technologies need China-specific demand data to prioritize market entry, localization, and sales strategies.

    Key Companies in the China Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Quantified market data for China showing $18.1M (2025) to $29.2M (2030) growth enables accurate budgeting, investment decisions, and competitive positioning in this high-growth segment.
    • China-Specific Growth Drivers : Understand unique factors accelerating China's 10% CAGR—government R&D initiatives, biotech ecosystem expansion, and personalized medicine adoption—unavailable in generic market reports.
    • Competitive Intelligence : Identify market opportunities and competitive gaps specific to China's preclinical research landscape, enabling targeted product development and go-to-market strategies for this region.
    • Regulatory & Infrastructure Insights : Gain clarity on China's evolving research infrastructure, funding mechanisms, and regulatory environment shaping demand for humanized models among pharmaceutical and biotech organizations.
    • Strategic Partnership Opportunities : Leverage China-focused market intelligence to identify potential collaborators, CROs, and research institutions driving adoption of humanized animal models in drug development.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in China?

    China's humanized mouse and rat model market was valued at $18.1 million in 2025 and is projected to reach $29.2 million by 2030.

    What is the expected growth rate for China's humanized mouse and rat model market?

    China's market is expected to grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2030, outpacing the global average.

    What factors are driving growth in China's humanized mouse and rat model market?

    Key drivers include increased government funding for life sciences research, expansion of contract research organizations, adoption by pharmaceutical companies, and regulatory reforms supporting preclinical research innovation in China.

    How does China's market growth compare to global trends?

    China's 10.0% CAGR exceeds the global market CAGR of 8.2%, reflecting China's accelerated investment in biotechnology and its strategic role in the global drug development supply chain.

    Which sectors in China are driving demand for humanized mouse and rat models?

    China's pharmaceutical companies, biotech startups, contract research organizations, and academic research institutions are the primary drivers of demand for humanized mouse and rat models.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status